PD-L1/HDAC-IN-1

PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM) . PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME[1].

Product Specifications

CAS Number

[2923313-69-1]

UNSPSC

12352005

Target

HDAC; PD-1/PD-L1

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

Field of Research

Cancer; Inflammation/Immunology

Smiles

N#CC1=CC=CC(COC(C=C(C(Cl)=C2)OCC3=C(C(C4=CC(OCCCCCCC(NO)=O)=CC=C4)=CC=C3)C)=C2CN5[C@H](CCCC5)C(O)=O)=C1

Molecular Formula

C42H46ClN3O7

Molecular Weight

740.28

References & Citations

[1]Yuan D, et al., Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors. J Enzyme Inhib Med Chem. 2025 Dec;40 (1) :2461190.